Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;7(1):37-51.
doi: 10.1517/17530059.2012.718329.

Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data

Affiliations

Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data

Jason E McDermott et al. Expert Opin Med Diagn. 2013 Jan.

Abstract

INTRODUCTION: The advent of high throughput technologies capable of comprehensive analysis of genes, transcripts, proteins and other significant biological molecules has provided an unprecedented opportunity for the identification of molecular markers of disease processes. However, it has simultaneously complicated the problem of extracting meaningful molecular signatures of biological processes from these complex datasets. The process of biomarker discovery and characterization provides opportunities for more sophisticated approaches to integrating purely statistical and expert knowledge-based approaches. AREAS COVERED: In this review we will present examples of current practices for biomarker discovery from complex omic datasets and the challenges that have been encountered in deriving valid and useful signatures of disease. We will then present a high-level review of data-driven (statistical) and knowledge-based methods applied to biomarker discovery, highlighting some current efforts to combine the two distinct approaches. EXPERT OPINION: Effective, reproducible and objective tools for combining data-driven and knowledge-based approaches to identify predictive signatures of disease are key to future success in the biomarker field. We will describe our recommendations for possible approaches to this problem including metrics for the evaluation of biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PCA-based visualization of a proteomics data biomarker study. (A) PCA was performed on a proteomics dataset with a simple limit-of-detection based imputation of missing data and (B) no imputation using Sequential Projection Pursuit. The axes in both plots represent the first principal component (X axes) and the second principal component (Y axes).
Figure 2
Figure 2
A. Coexpression network of macrophage response to nanoparticle exposure showing the progression of functional modules through time. B. Standard heatmap of macrophage transcriptional response to nanoparticle exposure with modules defined using hierarchical clustering.

References

    1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. Commentary. Provides detailed definitions and concepts of different types of biomarkers. - PubMed
    1. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845–856. Review. A comprehensive review on different types of cancer biomarkers. - PubMed
    1. Executive summary: Standards of medical care in diabetes. Diabetes Care. 2010;33(Suppl 1):S4–S10. - PMC - PubMed
    1. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol. 2011;29 (31):4160–4167. - PMC - PubMed
    1. Konecny G, Slamon DJ. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) 2002;16(11):1576, 1578. - PubMed

LinkOut - more resources